Therapy | Crohn's disease N = 27 | Ulcerative colitis N = 27 |
---|
Oral corticosteroids |
Yes | 24 (89%) | 15 (56%) |
No | 1 (4%) | 8 (30%) |
Missing data | 2 (7%) | 4 (15%) |
Oral 5-ASA |
Yes | 18 (67%) | 17 (63%) |
No | 7 (26%) | 6 (22%) |
Missing data | 2 (7%) | 4 (15%) |
Azathioprine |
Yes | 21 (78%) | 9 (33%) |
No | 4 (15%) | 14 (52%) |
Missing data | 2 (7%) | 4 (15%) |
Biologics |
Yes | 9 (33%) | 1 (4%) |
No | 16 (59%) | 22 (81%) |
Missing data | 2 (7%) | 4 (15%) |
- aData restricted to systemic medical therapy of 57 patients who had a validated (true) inflammatory bowel disease diagnosis on medical record review. Three patients with undefined inflammatory bowel disease (IBD) were not specifically reported in the table: three had oral corticosteroids, two with undefined IBD had 5-aminosalicylic acid (5-ASA), one had azathioprine and none of those three with undefined IBD had biologics